• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Helo Corp Welcomes Kevin Fuller as President of Helo AI

    12/12/23 8:30:00 AM ET
    $NUS
    $USNA
    Other Pharmaceuticals
    Health Care
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $NUS alert in real time by email

    SAN FRANCISCO, CA / ACCESSWIRE / December 12, 2023 / Helo Corp. (OTC:HLOC) ("Helo" or the "Company") is pleased to announce that Kevin Fuller has joined its executive team as president of Helo AI and chief marketing officer of Helo, effective December 1, 2023.

    "We are delighted to welcome Kevin to our executive team," said Seán McVeigh, Helo's chief executive officer. "Kevin brings significant product development and marketing experience, arising from his previous roles as a senior executive with other leading technology and wellness companies. His passion and leadership add to the significant momentum of our Helo AI platform and upcoming products."

    Mr. Fuller, 53, served as cofounder and chief executive officer of MACUVU Macular Health from 2022 to 2023. From 2005 to 2021, he served as Senior Vice President of Global Product & Brand, and in other roles at Nu Skin (NYSE:NUS). From 1997 to 2005, Mr. Fuller served as Senior Product Manager at USANA (NYSE:USNA). Mr. Fuller received an M.B.A. degree from Brigham Young University and a B.S. in Biology from the University of Utah.

    "Helo is transforming the wellness technology category through integration of biodata, artificial intelligence and personalized nutrition," said Mr. Fuller. "The Company's history of innovation and focus on data-driven wellness are very compelling, but Helo's future wellness ecosystem will transcend current digital wellness solutions. I am excited to join the talented Helo team in building the future of wellness and nutrition powered by AI."

    About Helo Corp.

    Helo Corp. (OTC:HLOC)  is a data-driven wellness technology company. Helo wearables and other smart devices are built on Helo's Life Sensing Technology®, which uses state-of-the-art sensors, enhanced signal processing, and algorithms to collect and process specific bio-parameters. Helo is developing the Helo AI platform to leverage artificial intelligence and other technologies to analyze wearer data to provide recommendations that support the adoption of healthier lifestyle choices to drive human wellness transformation.

    For more information please visit helocorp.com.

    The Company's disclosure statements and financial statements are available at OTC PINK:HLOC.

    Forward Looking Statements

    This news release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," and similar statements. All statements other than statements of historical fact in this press release are forward-looking statements and involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These forward-looking statements are based on management's current expectations, assumptions, estimates and projections about the Company and the industry in which the Company operates, but involve a number of unknown risks and uncertainties. Further information regarding these and other risks is included in the Company's filings with the OTC Markets and the Securities and Exchange Commission. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and actual results may differ materially from the anticipated results. You are urged to consider these factors carefully in evaluating the forward-looking statements contained herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements.

    Investors Contact:
    investors@helocorp.com
    650-646-2193

    SOURCE: Helo Corp.



    View the original press release on accesswire.com

    Get the next $NUS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NUS
    $USNA

    CompanyDatePrice TargetRatingAnalyst
    USANA Health Sciences Inc.
    $USNA
    6/23/2023Buy
    Sidoti
    Nu Skin Enterprises Inc.
    $NUS
    1/31/2023$43.00 → $39.00Buy → Hold
    Jefferies
    USANA Health Sciences Inc.
    $USNA
    7/7/2022$78.00 → $53.00Hold → Underperform
    Jefferies
    USANA Health Sciences Inc.
    $USNA
    4/14/2022$86.00Neutral
    DA Davidson
    Nu Skin Enterprises Inc.
    $NUS
    2/17/2022$47.00 → $50.00Neutral
    DA Davidson
    Nu Skin Enterprises Inc.
    $NUS
    11/24/2021$43.00 → $49.00Neutral
    Citigroup
    Nu Skin Enterprises Inc.
    $NUS
    10/6/2021$61.00 → $47.00Neutral
    DA Davidson
    More analyst ratings

    $NUS
    $USNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Winett James M was granted 26,643 shares and sold $40,481 worth of shares (7,203 units at $5.62) as part of a pre-agreed trading plan, increasing direct ownership by 108% to 37,448 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    6/3/26 5:10:22 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Director Nathanson Laura was granted 26,643 shares, increasing direct ownership by 87% to 57,116 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    6/3/26 5:09:32 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Director Zorko Mark A was granted 26,643 shares, increasing direct ownership by 78% to 60,586 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    6/3/26 5:08:41 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    $USNA
    SEC Filings

    View All

    SEC Form S-8 filed by Nu Skin Enterprises Inc.

    S-8 - NU SKIN ENTERPRISES, INC. (0001021561) (Filer)

    6/1/26 5:20:09 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - NU SKIN ENTERPRISES, INC. (0001021561) (Filer)

    5/29/26 4:05:27 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    SEC Form SD filed by Nu Skin Enterprises Inc.

    SD - NU SKIN ENTERPRISES, INC. (0001021561) (Filer)

    5/21/26 6:02:40 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    $USNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sidoti initiated coverage on USANA

    Sidoti initiated coverage of USANA with a rating of Buy

    6/23/23 9:12:38 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    Nu Skin downgraded by Jefferies with a new price target

    Jefferies downgraded Nu Skin from Buy to Hold and set a new price target of $39.00 from $43.00 previously

    1/31/23 6:17:27 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    USANA downgraded by Jefferies with a new price target

    Jefferies downgraded USANA from Hold to Underperform and set a new price target of $53.00 from $78.00 previously

    7/7/22 9:35:48 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $NUS
    $USNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Product Officer Hatchett Steven Keith bought $52,855 worth of shares (5,500 units at $9.61), increasing direct ownership by 3% to 167,565 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    11/12/25 4:32:45 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Chief Product Officer Hatchett Steven Keith bought $49,010 worth of shares (6,500 units at $7.54), increasing direct ownership by 4% to 162,065 units (SEC Form 4)

    4 - NU SKIN ENTERPRISES, INC. (0001021561) (Issuer)

    5/28/25 6:26:44 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    $USNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    USANA Earns Dual Best of State Honors for Product Innovation and Development

    USANA's CellSentials and Research and Development team honored at the awardsSALT LAKE CITY, June 4, 2026 /PRNewswire/ -- USANA, a leader in global nutrition, earned two Best of State awards in Salt Lake City, Utah, recognizing its CellSentials supplements and Research and Development team. USANA took home two Best of State medals this year in the following categories:Dietary Supplement—USANA CellSentials took home this honor for the tenth consecutive year Research and Development—USANA's R&D team won for the eighth timeTo learn more about USANA and its award-winning products, please visit USANA.com. "We are beyond honored to re

    6/4/26 6:47:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    Kevin Guest Encourages Professionals to Prioritize Wellness During Professional Wellness Month

    USANA CEO says small daily habits can strengthen health, improve workplace culture, and help others thriveSALT LAKE CITY, June 1, 2026 /CNW/ -- As Professional Wellness Month begins in June, Kevin Guest, Chairman and CEO of USANA Health Sciences (NYSE:USNA), is encouraging professionals, leaders, and organizations to make wellness a priority both at work and at home. He says healthier habits create stronger people, stronger teams, and stronger communities. Professional Wellness Month highlights the connection between personal well-being and workplace success. Research continues

    6/1/26 7:18:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    Nu Skin Enterprises Reports First Quarter Results

    Nu Skin Enterprises Inc. (NYSE:NUS) today announced first quarter revenue results within its guidance range. Executive Summary Q1 2026 vs. Prior-year Quarter Revenue $320.6 million; (12.0)%   • +1.1% FX impact or $3.9 million Earnings Per Share (EPS) $0.04 or $0.14 excluding certain charges compared to $2.14 or $0.23 excluding one-time gain from Mavely sale and other charges Customers 669,535; (14)% Paid Affiliates 120,850; (8)% Sales Leaders 26,915; (13)% "We delivered first quarter revenue in line with our expectations and made further progress in our strategic priorities while operating in a volatile environ

    5/7/26 4:06:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    $USNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

    SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

    11/12/24 4:47:17 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

    SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

    11/6/24 10:20:59 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

    SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

    11/4/24 10:21:31 AM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    $NUS
    $USNA
    Financials

    Live finance-specific insights

    View All

    Nu Skin Enterprises Reports First Quarter Results

    Nu Skin Enterprises Inc. (NYSE:NUS) today announced first quarter revenue results within its guidance range. Executive Summary Q1 2026 vs. Prior-year Quarter Revenue $320.6 million; (12.0)%   • +1.1% FX impact or $3.9 million Earnings Per Share (EPS) $0.04 or $0.14 excluding certain charges compared to $2.14 or $0.23 excluding one-time gain from Mavely sale and other charges Customers 669,535; (14)% Paid Affiliates 120,850; (8)% Sales Leaders 26,915; (13)% "We delivered first quarter revenue in line with our expectations and made further progress in our strategic priorities while operating in a volatile environ

    5/7/26 4:06:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Enterprises Announces Quarterly Dividend

    Nu Skin Enterprises, Inc. (NYSE:NUS) today announced its board of directors has declared a quarterly cash dividend of $0.06 per share, which will be paid on June 10, 2026, to shareholders of record on May 29, 2026. About Nu Skin Enterprises Inc. Nu Skin Enterprises Inc. (NYSE:NUS) is an intelligent beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by more than 40 years of scientific research, the company's products help people look, feel and live their best with our newly introduced Prysm iO intelligent wellness platform, an award-winning line of beauty device systems and trusted brands in personal car

    5/7/26 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    USANA Health Sciences Reports First Quarter 2026 Results

    Company Continues to Make Significant Progress on Transformation to Becoming a Leading Omnichannel Health and Wellness Platform USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal first quarter ended April 4, 2026. Key Financial Results First Quarter 2026 vs. First Quarter 2025 Net sales of $250 million versus $250 million. Net earnings of $7.5 million versus $9.4 million. Diluted EPS of $0.41 as compared with $0.49. Adjusted diluted EPS(1) of $0.61 as compared with $0.73. Adjusted EBITDA(2) of $28.4 million versus $29.8 million. Core Nutritional Active Customers of 404,000 versus 459,000. Hiya Active Monthly Subscribers of 186

    5/5/26 4:15:00 PM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care

    $NUS
    $USNA
    Leadership Updates

    Live Leadership Updates

    View All

    Nu Skin Enterprises Appoints Chelsea Lantz as Interim Chief Financial Officer

    Nu Skin Enterprises, Inc. (NYSE:NUS) today announced the appointment of Chelsea Lantz as interim Chief Financial Officer, effective immediately. The appointment of Lantz comes after James Thomas stepped down as CFO to pursue an outside opportunity. "On behalf of our board, management and the entire Nu Skin team, we thank James for his leadership and significant contributions over 16 years at Nu Skin and wish him and his family well in their future pursuits," said Ryan Napierski, president and CEO. "We have a talented finance team who has led the ongoing work to improve our operational performance and strengthen our balance sheet over the past year. I am excited to work directly with Chels

    3/20/26 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Nu Skin Appoints Chayce Clark as COO

    Clark to expand on his responsibilities as chief legal officer to oversee company operational functions and revenue performance Nu Skin Enterprises Inc. (NYSE:NUS) today announced the appointment of Chayce Clark as chief operating officer effective immediately. Clark will be responsible for leading the company's revenue performance and end-to-end operational execution across the business in addition to maintaining his role as the company's chief legal officer. "Chayce has been a valuable part of our executive team and an important voice in our efforts to become the world's leading intelligent beauty and wellness leadership opportunity platform," said Ryan Napierski, president and CEO. "

    3/9/26 4:05:00 PM ET
    $NUS
    Other Pharmaceuticals
    Health Care

    Kevin Guest Returns to USANA Health Sciences as CEO

    USANA Health Sciences, Inc. (NYSE:USNA) announced today a leadership transition as part of the Company's ongoing commitment to accelerating growth and enhancing shareholder value. Kevin Guest is returning to lead the Company as Chief Executive Officer, effective immediately. Mr. Guest, who has spent more than three decades at the Company, including eight years as CEO and the last three years as Executive Chairman, has agreed to again serve as USANA's CEO and will continue serving as Chairman. Mr. Guest succeeds Jim Brown, who has stepped down from his position of CEO and President. "We thank Jim for his contributions and his leadership over the past 19 years and in his role as CEO over th

    1/8/26 9:00:00 AM ET
    $USNA
    Medicinal Chemicals and Botanical Products
    Health Care